Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops
- PMID: 3363661
Treatment of severe vernal keratoconjunctivitis with cyclosporine A eyedrops
Abstract
Twenty-one children (4 to 12 years old) with severe vernal keratoconjunctivitis refractive to treatment with corticosteroid eyedrops and/or 2% disodium cromoglycate (Optic-rom, Fisons) were treated with CsA 2% eyedrops in oil solution. Eighteen patients (86%) experienced a rapid relief of their subjective symptoms three to four days after initiation of treatment. This was accompanied by objective improvement of ocular manifestations and visual acuity within a week. Sixteen of the children (76%) remained controlled during the 6-week period of treatment. However, only five patients (24%) did not need any additional therapy 2 months after discontinuation of the CsA eyedrops. These findings can be interpreted as an indication for the possible involvement of interleukin secretion in the clinical manifestations of vernal keratoconjunctivitis. Alternatively, the beneficial effects of CsA in this disease may be due to a direct effect on the mast cells preventing the release of their mediators.
Similar articles
-
Efficacy and safety of cyclosporine eyedrops in vernal keratoconjunctivitis.Ann Allergy Asthma Immunol. 2002 Sep;89(3):298-303. doi: 10.1016/S1081-1206(10)61958-8. Ann Allergy Asthma Immunol. 2002. PMID: 12269651 Clinical Trial.
-
[Cyclosporin A 2% eyedrops in therapy of atopic and vernal keratoconjunctivitis].Ophthalmologe. 2002 Oct;99(10):761-7. doi: 10.1007/s00347-001-0600-y. Ophthalmologe. 2002. PMID: 12376851 German.
-
Management of severe allergic conjunctivitis with topical cyclosporin a 0.05% eyedrops.Cornea. 2007 Oct;26(9):1035-8. doi: 10.1097/ICO.0b013e31812dfab3. Cornea. 2007. PMID: 17893529
-
Clinical grading of vernal keratoconjunctivitis.Curr Opin Allergy Clin Immunol. 2007 Oct;7(5):436-41. doi: 10.1097/ACI.0b013e3282efb726. Curr Opin Allergy Clin Immunol. 2007. PMID: 17873585 Review.
-
[New and future treatment approaches for allergic conjunctivitis].Ophthalmologie. 2024 Mar;121(3):180-186. doi: 10.1007/s00347-024-01996-9. Epub 2024 Feb 16. Ophthalmologie. 2024. PMID: 38363381 Review. German.
Cited by
-
Ocular pharmacokinetics and safety of ciclosporin, a novel topical treatment for dry eye.Clin Pharmacokinet. 2005;44(3):247-61. doi: 10.2165/00003088-200544030-00003. Clin Pharmacokinet. 2005. PMID: 15762768 Review.
-
The role and treatment of inflammation in dry eye disease.Int Ophthalmol. 2014 Dec;34(6):1291-301. doi: 10.1007/s10792-014-9969-x. Epub 2014 Jul 26. Int Ophthalmol. 2014. PMID: 25416345 Review.
-
Ocular allergy guidelines: a practical treatment algorithm.Drugs. 2002;62(11):1611-34. doi: 10.2165/00003495-200262110-00004. Drugs. 2002. PMID: 12109924 Review.
-
Cyclosporin. A review of its pharmacodynamic and pharmacokinetic properties, and therapeutic use in immunoregulatory disorders.Drugs. 1993 Jun;45(6):953-1040. doi: 10.2165/00003495-199345060-00007. Drugs. 1993. PMID: 7691501 Review.
-
Therapeutic options in ocular allergic disease.Drugs. 1995 Aug;50(2):208-21. doi: 10.2165/00003495-199550020-00002. Drugs. 1995. PMID: 8521755 Review.